Clinical features of metastatic bone disease and risk of skeletal morbidity
- PMID:17062708
- DOI: 10.1158/1078-0432.CCR-06-0931
Clinical features of metastatic bone disease and risk of skeletal morbidity
Abstract
The skeleton is the most common organ to be affected by metastatic cancer and the site of disease that produces the greatest morbidity. Skeletal morbidity includes pain that requires radiotherapy, hypercalcemia, pathologic fracture, and spinal cord or nerve root compression. From randomized trials in advanced cancer, it can be seen that one of these major skeletal events occurs on average every 3 to 6 months. Additionally, metastatic disease may remain confined to the skeleton with the decline in quality of life and eventual death almost entirely due to skeletal complications and their treatment. The prognosis of metastatic bone disease is dependent on the primary site, with breast and prostate cancers associated with a survival measured in years compared with lung cancer, where the average survival is only a matter of months. Additionally, the presence of extraosseous disease and the extent and tempo of the bone disease are powerful predictors of outcome. The latter is best estimated by measurement of bone-specific markers, and recent studies have shown a strong correlation between the rate of bone resorption and clinical outcome, both in terms of skeletal morbidity and progression of the underlying disease or death. Our improved understanding of prognostic and predictive factors may enable delivery of a more personalized treatment for the individual patient and a more cost-effective use of health care resources.
Similar articles
- Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline.Berruti A, Dogliotti L, Bitossi R, Fasolis G, Gorzegno G, Bellina M, Torta M, Porpiglia F, Fontana D, Angeli A.Berruti A, et al.J Urol. 2000 Oct;164(4):1248-53.J Urol. 2000.PMID:10992374
- The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J, Sung J, Raut M, Oster G.Delea T, et al.Oncology. 2004;67(5-6):390-6. doi: 10.1159/000082923.Oncology. 2004.PMID:15713995
- Skeletal complications of malignancy.Coleman RE.Coleman RE.Cancer. 1997 Oct 15;80(8 Suppl):1588-94. doi: 10.1002/(sici)1097-0142(19971015)80:8+<1588::aid-cncr9>3.3.co;2-z.Cancer. 1997.PMID:9362426Review.
- [Clinical features of pathologically confirmed metastatic bone tumors--a report of 390 cases].Xu DL, Zhang XT, Wang GH, Li FB, Hu JY.Xu DL, et al.Ai Zheng. 2005 Nov;24(11):1404-7.Ai Zheng. 2005.PMID:16552972Chinese.
- Biochemical approach to the detection and monitoring of metastatic bone disease: What do we know and what questions need answers?Tankó LB, Karsdal MA, Christiansen C, Leeming DJ.Tankó LB, et al.Cancer Metastasis Rev. 2006 Dec;25(4):659-68. doi: 10.1007/s10555-006-9024-0.Cancer Metastasis Rev. 2006.PMID:17160557Review.
Cited by
- Nox2 contributes to reactive oxygen species-induced redox imbalance in cancer-induced bone pain.Xu BY, Sun J, Chen SP, Wang XM, Chen N, Li DY, Chen G, Mei W, Tian YK, Zhou YQ, Ye DW.Xu BY, et al.Am J Transl Res. 2021 Mar 15;13(3):1269-1279. eCollection 2021.Am J Transl Res. 2021.PMID:33841655Free PMC article.
- Fracture Risk Prediction Using the Fracture Risk Assessment Tool in Individuals With Cancer.Ye C, Leslie WD, Al-Azazi S, Yan L, Lix LM, Czaykowski P, McCloskey EV, Johansson H, Harvey NC, Kanis JA, Singh H.Ye C, et al.JAMA Oncol. 2024 Nov 1;10(11):1554-1560. doi: 10.1001/jamaoncol.2024.4318.JAMA Oncol. 2024.PMID:39361310
- Bisphosphonates Versus Denosumab for Prevention of Pathological Fracture in Advanced Cancers With Bone Metastasis: A Meta-analysis of Randomized Controlled Trials.Al Farii H, Frazer A, Farahdel L, AlFayyadh F, Turcotte R.Al Farii H, et al.J Am Acad Orthop Surg Glob Res Rev. 2020 Aug;4(8):e20.00045. doi: 10.5435/JAAOSGlobal-D-20-00045.J Am Acad Orthop Surg Glob Res Rev. 2020.PMID:32769706Free PMC article.
- Finite element models for fracture prevention in patients with metastatic bone disease. A literature review.Sas A, Tanck E, Sermon A, van Lenthe GH.Sas A, et al.Bone Rep. 2020 May 26;12:100286. doi: 10.1016/j.bonr.2020.100286. eCollection 2020 Jun.Bone Rep. 2020.PMID:32551337Free PMC article.Review.
- Pharmacologic Hedgehog inhibition modulates the cytokine profile of osteolytic breast cancer cells.Bennett NE, Parker DV, Mangano RS, Baum JE, Northcutt LA, Miller JS, Beadle EP, Rhoades JA.Bennett NE, et al.J Bone Oncol. 2024 Jul 28;47:100625. doi: 10.1016/j.jbo.2024.100625. eCollection 2024 Aug.J Bone Oncol. 2024.PMID:39183755Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical